Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2060 SAD Study in Healthy Chinese Men
NCT06843993Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-2060 in thrombosis (4 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more adverse events (AEs) up to 164 days, Number of participants who discontinue study due to an AE up to 164 days and 1 more. Started Mar 2023; status: completed.
02
Drugs
MK-2060
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT06843993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843993.